Candesartan cilexetil: Development and preclinical studies

Drugs of Today

Volumn 35, Issue 2, 1999, Pages 105-115

  Gohlke, Peter ^a   Jurgensen T ^b   Von Kugelgen S ^b   Unger, Th ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACETIC ACID DERIVATIVE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; CANDESARTAN HEXETIL; COLLAGEN TYPE 2; COLLAGEN TYPE 3; DELAPRIL; ENALAPRIL; FIBRONECTIN; HYDRALAZINE; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; BRAIN PROTECTION; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART PROTECTION; HEMODYNAMICS; HORMONAL REGULATION; HYPERTENSION; INTRACEREBRAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0345683506     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.2.527966     Document Type: Review

References (46)

1. Edling, O., Gohlke, P., Paul, M. et al. The renin-angiotensin system: Physiology and pathophysiology. In: ACE Inhibitors: Current Use and Future Prospects. M. Schachter (Ed.). Martin Duniz: London 1995, S3-41.
2. Griendling, K.K., Lassègue, B., Alexander, R.W. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1997, 36: 281-306.
3. Bing, J., Poulson, K. Effect of anti-angiotensin II in blood pressure and sensitivity to angiotensin and renin. Acta Physiol Scand 1970, 78: 6-18.
4. Pals, D.T., Masucci, F.D., Sipos, F., Denning, G.S. Jr. A specific competitive antagonist of the vascular action of angiotensin II. Cire Res 1971, 29: 664-72.
5. Unger, T., Gohlke, P. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential. Cardiovasc Res 1994, 28: 146-58.
6. Timmermans, P.B.M.W.M., Wong, P.C., Chiu, A.T. et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45: 205-51.
7. Campbell, D.J., Kladis, A., Valentijn, A.J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995, 26: 233-40.
8. 2 recptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998, 31: 349-55.
9. Unger, T., Chung, O., Cikos, T. Angiotensin receptors. J Hypertens 1996, 14 (Suppl. 5): S95-103.
10. Furukawa, Y., Kishimoto, S., Nishikawa, K. (Takeda Chem., Ltd.). Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. US 4340598, US 4355040.
11. Kubo, K., Kohara, Y., Imamiya, E. et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993, 36: 2182-95.
12. Kubo, K., Kohara Y., Yoshimura Y. et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993, 36: 2343-9.
13. Noda, M., Shibouta, Y., Inada, Y. et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993, 46: 311-8.
14. Shibouta, Y., Inada, Y., Ojima, M. et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993, 266: 114-20.
15. 1 receptor. Eur J Pharmacol 1997, 319: 137-46.
16. Wada, T., Inada, Y., Sanada, T. et al. Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Pharmacol 1994, 253: 27-34.
17. Delacrétaz, E., Nussberger, J., Biollaz, J., Waeber, B., Brunner, H.R. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995, 25: 14-21.
18. Nagano, M., Higaki, J., Mikami, H., Ogihara, T. Role of the renin-angiotensin system in hypertension in the elderly. Blood Press 1994, 3 (Suppl. 5): 130-3.
19. Ogihara, T., Nagano, M., Kigaki, J., Kohara, K., Mikami, H. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 1995, 26: 490-4.
20. Hano, T., Mizukoshi, M., Baba, A., Nakamura, N., Nishio, I. Angiotensin II subtype 1 receptor modulates epinephrine release from isolated rat adrenal gland. Blood Press 1994, 3 (Suppl. 5): 105-8.
21. Dendorfer, A., Raasch, W., Tempel, K., Dominiak, P. Interactions between the reninangiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 1998, 93 (Suppl. 2): 24-9.
22. Yamada, K., Moriguchi, A., Mikami, H., Okuda, N., Higaki, J., Ogihara, T. The effect of central amino acid neurotransmitters on the antihypertensive response to angiotensin blockade in spontaneous hypertension. J Hypertens 1995, 13: 1624-30.
23. Inada, Y., Wada, T., Shibouta, Y. et al. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116), in various hypertensive rats. J Exp Pharmacol Ther 1994, 268: 1540-7.
24. Nishikawa, K., Inada, Y., Shibouta, Y. et al. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116. Blood Press 1994, 3 (Suppl. 5): 7-14.
25. 1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res 1996, 19: 75-81.
26. Ito, K., Shiomi, M., Kito, G. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 1995, 18: 69-75.
27. Li, X.C., Widdop, R.E. Angiotensin type II receptor antagonists CV-11974 and EXP-3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. Clin Sci 1996, 91: 147-54.
28. 1 receptor antagonist CV-11974 in conscious renal hypertensive rats Hypertension 1995, 26: 989-97.
29. Vraamark, T., Waldemar, G., Strandgaard, S., Paulson, O.B. Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregluation. J Hypertens 1995, 13: 755-61.
30. 1 receptor expression. Basic Res Cardiol 1998, 93 (Suppl. 2): 63-8.
31. Takeda, K., Fujita, H., Nakamura, K. et al. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 1994, 3 (Suppl. 5): 94-8.
32. Kagoshima, T., Masuda, J., Sutani, T. et al. Angiotensn II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press 1994, 3 (Suppl. 5): 89-93.
33. Kojima, M., Shiojima, I., Yamazaki, T. et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994, 89: 2204-11.
34. 1-receptor antagonist on gene expression and the cellular phenotype. J Hypertens 1997, 15 (Suppl. 6): S3-7.
35. Inada, Y., Wada, T., Ojima, M. et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997, 19: 1079-99.
36. 1 receptor antagonist, TCV-116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats. Clin Exp Pharmacol Physiol 1996, 23: 282-6.
37. Nishikimi, T., Yamagishi, H., Takeuchi, K., Takeda, T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995, 29: 856-61.
38. Yoshiyama, M., Kim, S., Yamagishi, H. et al. Cardioprotective effect of the angiotensin type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994, 128: 1-6.
39. Tanaka, A., Matsumori, A., Wang, W., Sasayama, S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994, 90: 2051-5.
40. Obata, J., Nakamura, T., Kuroyanagi, R., Yoshida, Y., Guo, D.F., Inagami, T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 1997, 63 (Suppl.): S229-31.
41. Noda, M., Fukuda, R., Matsuo, T. et al. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997, 63 (Suppl.): S136-9.
42. Okada, H., Suzuki, H., Kanno, Y. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995, 26: 564-9.
43. Kim, S., Ohta, K., Hamaguchi, A. et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994, 24: 195-204.
44. Wada, T., Kanagawa, R., Ishimura, Y., Inada, Y, Nishikawa, K. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 1995, 13: 113-22.
45. Nakamura, T., Obata, J., Onzuka, M. et al. Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int 1997, 63 (Suppl.): S226-8.
46. 1 receptor antagonist candesartan following peripheral application. Kidney Blood Press Res 1998, 21: 350-1.